Initial burst of viremia related to CD8 effector memory T cells after living donor liver transplantation in hepatitis C virus-infected recipients.
The post-transplant immune responses, viremia, and allograft histology after living donor liver transplantation were studied in 39 hepatitis C virus (HCV)-infected recipients. The recipients were classified into the following groups according to a hierarchical clustering of their preoperative CD8CD45 T-cell isoforms: group I, naive-dominant; group II, effector memory-dominant; and group III, effector-dominant. Plasma HCV-RNA rapidly increased and then peaked as an initial burst around postoperative day (POD) 25 in group I, on POD 40 in group II, and on POD 55 in group III. The initial burst of viremia was suppressed by the high expression of CD8+CD28-CD27- subsets. The progression of fibrosis > or =F2 was significantly more frequent for those patients with the highest viremia levels. Moreover, the initial T-cell immune response became less important throughout time, and new immune responses emerged after 2 months that modified the host-virus interaction. It is suggested that the interferon (IFN)-alpha/ribavirin therapy starting 2 months may be an effective option and now is undertaken.
Takada
Yasutsugu
Y
Department of Surgery, Graduate School of Medicine, Kyoto University, Kyoto, Japan.
Ozawa
Kazue
K
Egawa
Hiroto
H
Teramukai
Satoshi
S
Mori
Akira
A
Kaido
Toshimi
T
Kasahara
Mureo
M
Ogawa
Kohei
K
Ono
Masako
M
Sato
Hiroshi
H
Tanaka
Koichi
K
Uemoto
Shinji
S
D000893:Anti-Inflammatory Agents / Q000627:therapeutic use; D001706:Biopsy; D018414:CD8-Positive T-Lymphocytes / Q000276:immunology* / Q000821:virology; D003587:Cytomegalovirus / Q000276:immunology; D018450:Disease Progression; D005434:Flow Cytometry; D015497:HIV-1 / Q000276:immunology; D006526:Hepatitis C / Q000276:immunology* / Q000601:surgery*; D004854:Herpesvirus 4, Human / Q000276:immunology; D006801:Humans; D007156:Immunologic Memory; D017493:Leukocyte Common Antigens / Q000276:immunology; D016031:Liver Transplantation / Q000009:adverse effects* / Q000276:immunology* / Q000473:pathology; D019520:Living Donors; D008775:Methylprednisolone / Q000627:therapeutic use; D012367:RNA, Viral / Q000097:blood; D016176:T-Lymphocyte Subsets / Q000276:immunology / Q000821:virology; D013602:T-Lymphocytes, Cytotoxic / Q000276:immunology; D014184:Transplantation, Homologous / Q000276:immunology / Q000473:pathology; D019562:Viral Load; D014766:Viremia / Q000276:immunology*
D000893:Anti-Inflammatory Agents; D012367:RNA, Viral; D017493:Leukocyte Common Antigens; C516769:PTPRC protein, human; D008775:Methylprednisolone